04.10.25 -- Navigating The 2025 Medtech Regulatory Landscape In Switzerland And The U.K.

Though conducting your clinical trial in Australia may initially seem daunting, the benefits are ample. Australia is home to qualified CRO partners that will guide your CGT to regulatory success.

Discover how robotic gloveless isolator sterile fill-finish (SFF) systems can accelerate early-phase drug development, ensuring enhanced sterility and streamlined processes for biopharma innovation.

Review how an integrated platform approach and innovative filtration strategies helped bring a novel therapeutic to Phase 1 clinical trials with reduced time and costs.

Learn how a bioanalytical testing partner with comprehensive solutions and unwavering commitment to quality can help you bring safe and effective drugs to market with confidence.

To maximize drug development investments, it’s important to find a provider with solutions to optimize and accelerate the entire development timeline, from pipeline to market.

Palleos Oncology is a comprehensive solution designed to support pharmaceutical companies throughout the entire lifecycle of oncology treatment development.

Unearth several of the essential elements that constitute a successful HRPP to better protect the rights, safety, and welfare of research participants.

The release of the ICH E6(R3) Good Clinical Practice guideline in January 2025 marks a shift in clinical research, with significant implications for CROs, trial design, and quality management. 

Cell and gene therapy clinical trials require adaptive regulatory and operational strategies to address complex challenges, streamline patient engagement, and support successful development and delivery.

Navigating the intricate global regulatory path is crucial for clinical development success. See how expert-backed support has consistently propelled sponsors toward regulatory excellence.

Discover how offering sponsors end-to-end strategic drug development and technology-enabled regulatory services helps to reduce time, cost, and risk, from discovery through post-registration.